Lung Cancer
Conference Coverage
It Takes a Village: Treating Patients for NSCLC Brain Metastases
Multidisciplinary teams need to weigh options that may include immunotherapy, chemotherapy, targeted agents, and local therapy.
Latest News
ASCO Releases Vaccination Guidelines for Adults With Cancer
Oncologists may be key in ensuring patients with cancer safely receive vaccinations and avert avoidable infections.
Latest News
Tarlatamab Shows Promise in Tackling Previously Treated SCLC
Patients with SCLC showed improved survival and durable response to tarlatamab, which targets cancer cells that express DLL3.
Conference Coverage
Debate: Does ctDNA Have Role in Monitoring Tx Efficacy in Lung Cancer?
Experts debate whether liquid biopsy can provide useful clinical information beyond prognostication in the postoperative setting.
Conference Coverage
Savolitinib Active Against MET Ex14 Mutated NSCLC
Savolitinib was associated with similar progression-free survival as both first- and second-line therapy for patients with locally advanced or...
From the Journals
Few Childhood Cancer Survivors Get Recommended Screenings
‘As many as four out of five of these survivors will develop a serious or life-threatening late effect of their cancer therapy by age 45,’ the...
Latest News
Subcutaneous Immunotherapy Promises Better Life For Cancer Patients
A move toward subcutaneous versions of standard biologics means less time in clinic for physicians and patients.
Conference Coverage
Lung Cancer Screening Unveils Hidden Health Risks
An ongoing trial is using lung cancer screening CT scans to also look for signs of impending heart disease in 24,000 Europeans.
Conference Coverage
Upfront Low-Dose Radiation Improves Advanced SCLC Outcomes
Researchers compared their new findings with those of standard first-line treatment results from the 2019 CASPIAN trial.
From the Journals
Most Cancer Trial Centers Located Closer to White, Affluent Populations
Researchers compare the distributions of patients of different races and socioeconomic statuses to the locations of clinical research facilities...
Commentary
New Drug Approvals Are the Wrong Metric for Cancer Policy
How should we define success in cancer policy — what should the endpoint be?